MK0773

Merck Sharp & Dohme LLC · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	MK0773
Sponsor	Merck Sharp & Dohme LLC
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety, Tolerability and Efficacy of MK0773 in Healthy Postmenopausal Women (0773-003) (PHASE1)
Safety and Tolerability of MK0773 in Healthy Older Men (0773-004) (PHASE1)
A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(MK-0773-005) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MK0773 CI brief — competitive landscape report
MK0773 updates RSS · CI watch RSS
Merck Sharp & Dohme LLC portfolio CI